<DOC>
	<DOC>NCT01213758</DOC>
	<brief_summary>Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy. This technique provides volumetric mapping of liver function and it allows quantisation of liver function. The method may be used for selection of patients for stereotactic radiotherapy of liver tumors, for determination of radiation induced liver dysfunction and may be included into the treatment planning process of stereotactic radiotherapy.</brief_summary>
	<brief_title>Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>liver tumor referred for stereotactic radiation therapy age &gt; 18 years Impaired kidney function Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>liver function</keyword>
	<keyword>galactose</keyword>
	<keyword>18-F-deoxy-galactose</keyword>
	<keyword>PET/CT</keyword>
	<keyword>stereotactic body radiation therapy</keyword>
	<keyword>SBRT</keyword>
</DOC>